TABLE OF CONTENTS
1 INTRODUCTION 119
1.1 OBJECTIVES OF THE STUDY 119
1.2 MARKET DEFINITION 119
1.3 OVERVIEW OF THE NORTH AMERICA ANTIVIRAL DRUGS MARKET 119
1.4 LIMITATIONS 121
1.5 MARKETS COVERED 121
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PRODUCT TYPE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET TESTING TYPE COVERAGE GRID 136
2.11 VENDOR SHARE ANALYSIS 137
2.12 SECONDARY SOURCES 138
2.13 ASSUMPTIONS 138
3 EXECUTIVE SUMMARY 139
4 PREMIUM INSIGHTS 142
4.1 PORTERS FIVE FORCES 143
4.2 PESTEL ANALYSIS 144
5 EPIDEMIOLOGY 145
6 PIPELINE ANALYSIS FOR NORTH AMERICA ANTIVIRAL DRUGS MARKET 146
7 REGULATORY FRAMEWORK 147
8 MARKET OVERVIEW 149
8.1 DRIVERS 151
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153
8.2 RESTRAINS 154
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154
8.3 OPPORTUNITIES 155
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156
8.4 CHALLENGES 157
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158
9 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION 159
9.1 OVERVIEW 160
9.2 INFLUENZA 163
9.2.1 NEURAMINIDASE INHIBITORS 164
9.2.1.1 OSELTAMIVIR 164
9.2.1.2 ZANAMIVIR 164
9.2.1.3 PERAMIVIR 164
9.2.1.4 LANINAMIVIR 164
9.2.2 M2 INHIBITORS 165
9.2.2.1 RIMANTADINE 165
9.2.2.2 OTHERS 165
9.2.3 RNA POLYMERASE INHIBITORS 165
9.2.3.1 FAVIPIRAVIR 165
9.2.3.2 BALOXAVIR MARBOXIL 165
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167
9.3.1.1 NUCLEOSIDE (NRTIS) 167
9.3.1.1.1 LAMIVUDINE 168
9.3.1.1.2 ABACAVIR 168
9.3.1.1.3 DIDANOSINE 168
9.3.1.1.4 OTHERS 168
9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168
9.3.1.2.1 EFAVIRENZ 168
9.3.1.2.2 NEVIRAPINE 168
9.3.1.2.3 DELAVIRDINE 168
9.3.1.2.4 OTHERS 169
9.3.1.3 INTEGRASE 169
9.3.1.3.1 DOLUTEGRAVIR 169
9.3.1.3.2 ELVITEGRAVIR 169
9.3.1.3.3 RALTEGRAVIR 169
9.3.1.3.4 BICTEGRAVIR 169
9.3.1.4 NUCLEOTIDE 169
9.3.1.4.1 TENOFOVIR 170
9.3.1.4.2 OTHERS 170
9.3.1.5 INTERFERONS 170
9.3.1.5.1 ALPHA 170
9.3.1.5.2 BETA 170
9.3.1.5.3 GAMMA 171
9.3.1.6 GP41 171
9.3.1.6.1 ENFUVIRTIDE 171
9.3.1.6.2 OTHERS 171
9.3.2 PROTEASE 172
9.3.2.1 ATAZANAVIR 172
9.3.2.2 DARUNAVIR 172
9.3.2.3 LOPINAVIR 172
9.3.2.4 RITONAVIR 172
9.3.2.5 SAQUINAVIR 172
9.3.2.6 INDINAVIR 172
9.3.2.7 NELFINAVIR 173
9.3.2.8 TIPRANAVIR 173
9.3.2.9 AMPRENAVIR 173
9.4 HEPATITIS C VIRUS 173
9.4.1 NS5B POLYMERASE 174
9.4.1.1 SOFOSBUVIR 174
9.4.1.2 DASABUVIR 174
9.4.2 NS3/4A PROTEASE 175
9.4.2.1 DANOPREVIR 175
9.4.2.2 GLECAPREVIR 175
9.4.2.3 GRAZOPREVIR 175
9.4.2.4 PARITAPREVIR 175
9.4.2.5 SIMEPREVIR 175
9.4.3 NS5A PHOSPHOPROTEIN 176
9.4.3.1 LEDIPASVIR 176
9.4.3.2 VELPATASVIR 176
9.4.3.3 OMBITASVIR 176
9.4.3.4 ELBASVIR 176
9.4.3.5 DACLATASVIR 176
9.4.3.6 PIBRENTASVIR 176
9.4.4 NEURAMINIDASE 177
9.4.4.1 OSELTAMIVIR 177
9.4.4.2 ZANAMIVIR 177
9.4.4.3 PERAMIVIR 177
9.4.4.4 LANINAMIVIR 177
9.4.5 RNA POLYMERASE 177
9.4.5.1 BALOXAVIR MARBOXIL 178
9.4.5.2 FAVIPIRAVIR 178
9.4.6 MATRIX PROTEIN 2 178
9.4.6.1 RIMATIDINE 178
9.4.6.2 FAVIPIRAVIR 178
9.5 HERPES SIMPLEX VIRUS 179
9.5.1 DNA POLYMERASE UL30 180
9.5.1.1 ACICLOVIR 180
9.5.1.2 FAMCICLOVIR 180
9.5.1.3 VALACICLOVIR 180
9.5.1.4 PENCICLOVIR TRIFLURIDINE 180
9.5.1.5 BRIVUDINE 180
9.5.1.6 FOSCARNET 180
9.5.1.7 IDOXURIDINE 181
9.5.2 ENVELOPE PROTEINS 181
9.5.2.1 DOCOSANOL 181
9.5.2.2 OTHERS 181
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181
9.6.1 GANCICLOVIR 182
9.6.2 VALGANCICLOVIR 182
9.6.3 CIDOFOVIR 182
9.6.4 FOSCARNET 182
9.6.5 FOMIVIRSEN 182
9.7 VARICELLA-ZOSTER VIRUS (VZV) 183
9.7.1 VALACICLOVIR 184
9.7.2 FAMCICLOVIR 184
9.7.3 ACICLOVIR 184
9.7.4 VIDARABINE 184
9.7.5 BRIVUDINE 184
9.8 HEPATITIS B VIRUS 184
9.8.1 ENTECAVIR 185
9.8.2 TENOFOVIR 185
9.8.3 TELBIVUDINE 185
9.8.4 TENOFOVIR ALAFENAMIDE 186
9.8.5 OTHERS 186
9.9 RESPIRATORY SYNCYTIAL VIRUS 186
9.9.1 RNA POLYMERASE 187
9.9.1.1 RIBAVIRIN 187
9.9.1.2 OTHERS 187
9.9.2 FUSION GLYCOPROTEIN 187
9.9.2.1 PALIVIZUMAB 188
9.9.2.2 OTHERS 188
9.10 CORONAVIRUS INFECTION 188
9.11 OTHERS 189
10 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190
10.1 OVERVIEW 191
10.2 GERIATRIC 194
10.2.1 MALE 194
10.2.2 FEMALE 194
10.3 CHILD 195
10.3.1 MALE 195
10.3.2 FEMALE 196
10.4 ADULT 196
10.4.1 MALE 197
10.4.2 FEMALE 197
11 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198
11.1 OVERVIEW 199
11.2 ORAL 202
11.2.1 SOLID 203
11.2.1.1 TABLETS 203
11.2.1.2 CAPSULES 203
11.2.1.3 OTHERS 203
11.2.2 SEMISOLID 203
11.2.2.1 GELS 204
11.2.2.2 EMULSIONS 204
11.2.2.3 ELIXIRS 204
11.2.2.4 OTHERS 204
11.2.3 LIQUID 204
11.2.3.1 SOLUTIONS 204
11.2.3.2 SYRUPS 204
11.2.3.3 OTHERS 204
11.3 TOPICAL 205
11.3.1 SEMI-SOLID 206
11.3.1.1 CREAM 206
11.3.1.2 OINTMENT 206
11.3.1.3 GELS 206
11.3.1.4 OTHERS 206
11.3.2 LIQUID 206
11.3.2.1 SOLUTIONS 207
11.3.2.2 SUSPENSIONS 207
11.3.3 SOLID 207
11.3.3.1 POWDERS 207
11.3.3.2 SUPPOSITORIES 207
11.3.3.3 ENEMA 207
11.3.3.4 OTHERS 207
11.4 PARENTERAL 208
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209
11.4.1.1 SOLUTIONS 209
11.4.1.2 RECONSTITUTED/LYOPHILIZED 209
11.4.1.3 SUSPENSIONS 209
11.4.1.4 EMULSIONS 209
11.4.1.5 OTHERS 209
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210
11.4.3 COLLOIDAL DISPERSIONS 210
11.4.4 LONG ACTING INJECTION FORMULATION 210
12 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211
12.1 OVERVIEW 212
12.2 GENERIC 215
12.3 BRANDED 215
13 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY END USER 216
13.1 OVERVIEW 217
13.2 HOSPITAL 220
13.3 SPECIALTY CENTERS 220
13.4 AMBULATORY CENTRES 221
13.5 CLINICS 221
13.6 HOME HEALTHCARE 221
13.7 OTHERS 222
14 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223
14.1 OVERVIEW 224
14.2 HOSPITAL PHARMACY 227
14.3 RETAIL PHARMACY 227
14.4 ONLINE PHARMACY 228
15 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY REGION 229
15.1 NORTH AMERICA 230
15.1.1 U.S. 253
15.1.2 CANADA 272
15.1.3 MEXICO 289
16 NORTH AMERICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 307
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 307
17 SWOT ANALYSIS 308
18 COMPANY PROFILE 309
18.1 GILEAD SCIENCES, INC. (2022) 309
18.1.1 COMPANY SNAPSHOT 309
18.1.2 REVENUE ANALYSIS 309
18.1.3 COMPANY SHARE ANALYSIS 310
18.1.4 PRODUCT PORTFOLIO 310
18.1.5 RECENT DEVELOPMENT 310
18.2 PFIZER INC. (2022) 311
18.2.1 COMPANY SNAPSHOT 311
18.2.2 REVENUE ANALYSIS 311
18.2.3 COMPANY SHARE ANALYSIS 312
18.2.4 PRODUCT PORTFOLIO 312
18.2.5 RECENT DEVELOPMENTS 312

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.